Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Lancet
; 389(10073): 1011-1024, 2017 03 11.
Article
in En
| MEDLINE
| ID: mdl-28129987
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Pancreatic Ductal
/
Deoxycytidine
/
Capecitabine
/
Antimetabolites, Antineoplastic
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet
Year:
2017
Document type:
Article
Country of publication:
United kingdom